Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
European Psychiatry : the Journal of the Association of European Psychiatrists|September 21, 2005
Patient outcomes in schizophrenia II: the impact of cognitionAlex Hofer, Susanne Baumgartner, Thomas Bodner, et al.
Schizophrenia Research|July 19, 2016
Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trialSuresh Durgam, Willie Earley, Rui Li, et al.
The International Journal of Neuropsychopharmacology|July 23, 2011
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaW Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychoticW Wolfgang Fleischhacker, Mariëlle Eerdekens, Keith Karcher, et al.
Schizophrenia Research|February 29, 2016
Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)Karin Landolt, Wulf Rössler, Vladeta Ajdacic-Gross, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 25, 2018
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studiesStephen Marder, W Wolfgang Fleischhacker, Willie Earley, et al.
Psychiatry Research|April 6, 2010
Attitudes of patients with schizophrenia and depression towards psychiatric researchMonika Edlinger, Eberhard A Deisenhammer, Michaela Fiala, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 26, 2012
Treatment of depression in first episode of schizophrenia: results from EUFESTJanusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, et al.
Schizophrenia Research|July 30, 2013
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose studySuresh Mallikaarjun, John M Kane, Patricia Bricmont, et al.
The Journal of Clinical Psychiatry|April 29, 2003
Attitudes of patients with schizophrenia toward placebo-controlled clinical trialsMartina Hummer, Roswitha Holzmeister, Georg Kemmler, et al.
Pageof 18